Arthritis therapy may impact rates of unplanned pregnancy

Article

Exposure to anti-tumor necrosis factor (anti-TNF) drugs for rheumatoid arthritis (RA) rather than methotrexate may be associated with increased rates of induced abortion, according to the results of a nested case-control study by Canadian researchers. The findings, say the investigators, point to a need for contraceptive counseling for women being treated for RA to lower the likelihood of unplanned pregnancy.

 

Exposure to anti-tumor necrosis factor (anti-TNF) drugs for rheumatoid arthritis (RA) rather than methotrexate may be associated with increased rates of induced abortion, according to the results of a nested case-control study by Canadian researchers. The findings, say the investigators, point to a need for contraceptive counseling for women being treated for RA to lower the likelihood of unplanned pregnancy.

Published in Arthritis Care and Research, the analysis was based on information from Quebec’s physician billing and hospitalization databases from 1996 to 2008. Women aged 15 to 45 with RA were identified, with cases defined as those who had an induced abortion and 5,855 controls being women with RA who had not undergone the procedure. Each case was matched to a control for age, calendar time, and cohort entry. Exposure was defined as having filled one prescription for methotrexate 16 weeks or less before the index date.

The researchers identified 112 women with RA who had induced abortions. Nearly 11% of cases and 22% of controls were exposed to methotrexate. The rate of induced abortions was lower in those exposed to methotrexate (RR 0.74; 95% CI 0.25, 0.89) than in those who received an anti-TNF agent. In multivariate analysis, a trend was seen toward an increased rate of induced abortions in those who had taken the anti-TNF agents (RR 2.07; 95% CI 0.81, 5.27).

“These findings,” said lead author Evelyne Vinet, MD, “highlight the importance of research on reducing the number of unplanned pregnancies in women with RA taking MTX or TNF inhibitors. Further examination of counseling practices and contraceptive use is warranted to further reduce the need for abortions in women with RA.”

Recent Videos
Rossella Nappi, MD, discusses benefits of fezolinetant against vasomotor symptoms | Image Credit: imsociety.org
How AI is revolutionizing breast cancer detection | Image Credit: simonmed.com
Understanding cardiovascular risk factors in women | Image Credit: cedars-sinai.org.
Christie Hilton, DO, discusses breast cancer management | Image Credit: findcare.ahn.org
Updated FLUBLOK label expands influenza vaccine options for pregnant women | Image Credit: mass-vaccination-resources.org
Sheryl Kingsberg, PhD: Psychedelic RE104 for postpartum depression
Mammograms may reveal hidden cardiovascular risks, study finds | Image Credit: providers.ucsd.edu
Erika Hamilton highlights emerging breast cancer trends and advances in treatment | Image Credit: sarahcannon.com
JoAnn Pinkerton discusses elinzanetant's crucial role in VMS therapy | Image Credit: uvahealth.com
Related Content
© 2024 MJH Life Sciences

All rights reserved.